CHMP recommends approval of Reblozyl for transfusion-dependent anemia due to very low-, low- and intermediate-risk myelodysplastic syndromes and transfusion-dependent anemia associated with beta thalassemia.- BMS + Acceleron
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest